Radiopharmaceutical Therapies Market to reach US$31.65bn
The global radiopharmaceutical therapies market is estimated at US$7.65 billion in 2026 and is projected to reach US$31.65 billion by 2036, growing at a CAGR of 15.3% during the forecast period 2026-2036.
Expanding regulatory approvals, an advancing actinium-225 clinical pipeline and growing investment in isotope supply infrastructure are driving rapid commercial development in the radiopharmaceutical therapies market. U.S. Section 232 tariff measures are adding a further dimension to sourcing and manufacturing decisions across the sector.
Key Market Growth Drivers & Industry Transformations
Growing Clinical and Regulatory Momentum for Radioligand Therapy: Clinical evidence and broader regulatory approvals are extending radioligand therapies into earlier treatment settings, increasing the eligible patient population and supporting demand for therapeutic doses. In July 2026, the FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, extending its use to an earlier disease stage. In March 2025, the FDA had already expanded the Pluvicto label to include use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer, which Novartis estimated approximately tripled the eligible patient population.
Expansion of Theranostics Adoption: Theranostics supports the adoption of radiopharmaceutical therapies by linking molecular imaging with treatment directed at the same biological target, helping to identify eligible patients and support referrals for targeted radionuclide treatment. Established applications include PSMA-targeted imaging in prostate cancer and somatostatin receptor imaging in neuroendocrine tumours. A 2025 review reported more than 400 radioligand therapy trials registered as of July 2025, investigating additional molecular targets, alternative radionuclides and combination treatments, with the potential to expand future treatment options subject to clinical validation and regulatory approval.
Emerging Alpha-Emitter Pipeline: The development of actinium-225 and lead-212 therapies is creating opportunities across drug development, isotope production and specialised manufacturing. In October 2026, Bristol Myers Squibb reported that RYZ101 (225Ac-DOTATATE) met its primary progression-free survival endpoint at the interim analysis of the Phase III ACTION-1 trial in patients with gastroenteropancreatic neuroendocrine tumours, providing late-stage evidence for actinium-225-based treatment. In May 2026, TerraPower Isotopes began construction of a US$450 million actinium-225 manufacturing facility in Philadelphia to ease supply constraints and support clinical development and potential commercial launches.
Strategic CDMO and Isotope-Supply Partnerships: The specialised production requirements of radiopharmaceutical therapies are driving CDMO and isotope supply partnerships as clinical programmes advance. Niowave entered an actinium-225 supply agreement with Novartis in February 2026, following the expansion of its AstraZeneca agreement to a 10-year commitment in December 2025. Ratio Therapeutics expanded its collaboration with PharmaLogic in May 2026 to increase clinical manufacturing capacity for its actinium-225-based FAP-targeted candidate. Consolidation is also advancing, with Curium agreeing to acquire Lantheus for up to US$8.0 billion in August 2026, with completion expected in the first half of 2027.
Impact of U.S. Trade Tariffs: Presidential Proclamation 11020, issued on 2 April 2026, established a default Section 232 tariff of 100% on covered patented pharmaceuticals and associated ingredients. Nuclear medicines and associated ingredients can qualify for a zero Section 232 tariff when product and origin conditions are satisfied. China is absent from the guidance’s list of eligible jurisdictions, making alternative relief provisions particularly relevant to covered Chinese-origin imports. Manufacturers are therefore reassessing sourcing, supplier selection and future manufacturing locations in light of tariff exposure.
What This Means for the Market
The radiopharmaceutical therapies market is entering a period of accelerating commercial and clinical development. Expanding Pluvicto approvals are broadening the eligible patient population for the leading lutetium-177 therapy, while the actinium-225 pipeline is generating late-stage clinical data that supports investment in isotope supply and manufacturing capacity. Strategic acquisitions and long-term supply agreements are reshaping the competitive landscape, and U.S. tariff measures are influencing sourcing and manufacturing decisions across the sector.
Scope of the Visiongain Report
Radioisotope Type: Lutetium-177; Actinium-225; Yttrium-90; Iodine-131; Radium-223; Others
Therapy Type: Non-PRRT Radioligand Therapy (RLT); Peptide Receptor Radionuclide Therapy (PRRT); Targeted Alpha Therapy (TAT); Radioimmunotherapy; Brachytherapy & Others
Indication: Prostate Cancer; Neuroendocrine Tumors (NETs); Thyroid Cancer; Lymphoma; Bone Metastases; Others
End User: Hospitals; Specialty & Comprehensive Cancer Centers; Diagnostic & Nuclear Medicine Imaging Centers; Others
Regions: North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
National Markets: U.S., Canada, Germany, UK, France, Italy, Spain, Switzerland, Poland, Belgium, Netherlands, Japan, China, India, Australia, South Korea, Brazil, Mexico, GCC, South Africa and Egypt
Competitive Landscape
The radiopharmaceutical therapies market features a mix of large pharmaceutical companies, specialist radiopharmaceutical firms, isotope producers and contract manufacturers pursuing strategic initiatives including acquisitions, manufacturing capacity expansions, long-term isotope supply agreements and research partnerships.
- Actinium Pharmaceuticals, Inc.
- ARTBIO, Inc.
- AdvanCell Pty Ltd.
- Ariceum Therapeutics
- Bayer AG
- Bracco Imaging S.p.A.
- Bristol Myers Squibb Company (RayzeBio)
- Cardinal Health, Inc.
- Clarity Pharmaceuticals Ltd.
- Convergent Therapeutics, Inc.
- Curium Holding France S.A.S
- Eckert & Ziegler
- Eli Lilly and Company
- Fusion Pharmaceuticals Inc. (AstraZeneca)
- GE HealthCare Technologies Inc.
- ITM Isotope Technologies Munich SE
- Lantheus Holdings, Inc.
- NorthStar Medical Technologies, LLC (NorthStar)
- Novartis AG
- Orano Med
- Perspective Therapeutics, Inc.
- RadioMedix, Inc.
- Ratio Therapeutics, Inc.
- Siemens Healthineers AG
- Telix Pharmaceuticals Limited
Recent Developments
- 12 October 2026: Bristol Myers Squibb reported that the Phase III ACTION-1 trial of RYZ101 (225Ac-DOTATATE) in patients with GEP-NETs met its primary progression-free survival endpoint at an interim analysis.
- 22 September 2026: The FDA granted final approval to Lantheus’s ANDA-based lutetium Lu 177 dotatate product, marketed as Bravnetsa.
- 10 August 2026: ITM announced that the FDA had issued a Complete Response Letter for 177Lu-edotreotide (ITM-11), citing chemistry, manufacturing and controls issues, with resubmission planned.
- 3 August 2026: Curium agreed to acquire Lantheus for up to US$8.0 billion, with completion expected in the first half of 2027.
- 31 July 2026: The FDA approved Novartis’s Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer.
- May 2026: TerraPower Isotopes began construction of a US$450 million actinium-225 manufacturing facility in Philadelphia.
- May 2026: Ratio Therapeutics expanded its collaboration with PharmaLogic to increase clinical manufacturing capacity for its actinium-225-based FAP-targeted candidate RTX-2358.
- April 2026: Presidential Proclamation 11020 established a default Section 232 tariff of 100% on covered patented pharmaceuticals, with nuclear medicines eligible for a zero tariff when product and origin conditions are satisfied.
Related Visiongain Market Reports
About Visiongain
Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.
Media Contact
press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com
